Artivion (NYSE:AORT) Price Target Raised to $42.00
JMP Securities has raised the price target for Artivion (NYSE:AORT) from $33.00 to $42.00, maintaining a "market outperform" rating. This suggests a potential upside of 7.93% from the previous close. Other analysts have also increased their targets, with Stifel Nicolaus setting it at $40.00 and Needham & Company at $45.00. Artivion's stock rose 19.0% to $38.92, with a consensus rating of "Buy" and an average target price of $38.80. The company reported a quarterly EPS of $0.24, exceeding estimates, and a revenue increase of 15.3% year-over-year.
Artivion (NYSE:AORT - Get Free Report) had its price objective upped by equities researchers at JMP Securities from $33.00 to $42.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a "market outperform" rating on the stock. JMP Securities' price objective suggests a potential upside of 7.93% from the company's previous close.
A number of other equities research analysts have also recently weighed in on AORT. Stifel Nicolaus boosted their price objective on Artivion from $36.00 to $40.00 and gave the company a "buy" rating in a research note on Friday. Canaccord Genuity Group started coverage on Artivion in a report on Tuesday, June 17th. They issued a "buy" rating and a $35.00 target price on the stock. Citizens Jmp raised Artivion to a "strong-buy" rating in a report on Tuesday, May 6th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $45.00 target price (up previously from $32.00) on shares of Artivion in a report on Friday. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $38.80.
Check Out Our Latest Analysis on Artivion
Artivion Trading Up 19.0%
Shares of NYSE AORT traded up $6.22 during trading on Friday, hitting $38.92. 541,252 shares of the company were exchanged, compared to its average volume of 419,484. The company has a fifty day moving average price of $30.55 and a 200-day moving average price of $27.96. The company has a debt-to-equity ratio of 1.08, a quick ratio of 3.95 and a current ratio of 5.53. The firm has a market capitalization of $1.66 billion, a PE ratio of -77.80 and a beta of 1.64. Artivion has a 12-month low of $21.97 and a 12-month high of $40.56.
Artivion (NYSE:AORT - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.13. Artivion had a positive return on equity of 3.63% and a negative net margin of 5.49%. The company had revenue of $112.97 million during the quarter, compared to the consensus estimate of $107.96 million. Artivion's quarterly revenue was up 15.3% on a year-over-year basis. As a group, equities research analysts expect that Artivion will post 0.37 EPS for the current year.
Insiders Place Their Bets
In other news, Director Anthony B. Semedo sold 2,600 shares of the stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $28.47, for a total value of $74,022.00. Following the completion of the sale, the director owned 33,059 shares in the company, valued at approximately $941,189.73. This trade represents a 7.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Jean F. Holloway sold 8,748 shares of the stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $29.00, for a total value of $253,692.00. Following the completion of the sale, the senior vice president owned 178,510 shares of the company's stock, valued at approximately $5,176,790. This trade represents a 4.67% decrease in their position. The disclosure for this sale can be found here. Insiders sold 62,406 shares of company stock worth $1,801,262 over the last three months. 7.60% of the stock is owned by insiders.
Institutional Investors Weigh In On Artivion
Hedge funds have recently bought and sold shares of the business. Franklin Resources Inc. lifted its holdings in shares of Artivion by 2.8% in the 4th quarter. Franklin Resources Inc. now owns 21,707 shares of the company's stock worth $621,000 after purchasing an additional 600 shares during the last quarter. Illinois Municipal Retirement Fund lifted its holdings in shares of Artivion by 3.1% in the 1st quarter. Illinois Municipal Retirement Fund now owns 20,519 shares of the company's stock worth $504,000 after purchasing an additional 611 shares during the last quarter. MCF Advisors LLC lifted its holdings in shares of Artivion by 109.3% in the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock worth $29,000 after purchasing an additional 614 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Artivion by 3.3% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,559 shares of the company's stock worth $645,000 after purchasing an additional 727 shares during the last quarter. Finally, Barclays PLC lifted its holdings in shares of Artivion by 1.2% in the 4th quarter. Barclays PLC now owns 71,697 shares of the company's stock worth $2,051,000 after purchasing an additional 820 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company's stock.
Artivion Company Profile
(Get Free Report)Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
Recommended Stories
- Five stocks we like better than Artivion
- Investing in Travel Stocks Benefits
- Tesla Is Balanced on a Knife Edge: Time to Tread Carefully
- What is a Secondary Public Offering? What Investors Need to Know
- Why Axon's 16% Surge Signals a New Era in Public Safety Tech
- EV Stocks and How to Profit from Them
- DraftKings Posts Record Quarter, Eyes Profitability
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Artivion Right Now?
Before you consider Artivion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artivion wasn't on the list.
While Artivion currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
